PureHealth achieved a robust 52% year-on-year revenue increase to USD 1.7 billion in Q1 2024, driven by ongoing organic growth and successfully completed strategic acquisitions. EBITDA surged by 127% year-on-year to around USD 294 million, with operational efficiencies improving across all key segments. The EBITDA margin rose to around 18% in Q1 2024 from 12% in Q1 2023. PureHealth has a Net Cash balance of c. USD 1.2 Billion (excluding lease liabilities) on 31 March 2024, resulting in a Net Cash to EBITDA (LTM 31 March 2024) ratio of (1.45x). ABU DHABI, UAE, May 2, 2024 /PRNewswire/ -- Pure Health Holding PJSC ("PureHealth" or "the Group") (ADX Symbol: PUREHEALTH) (ISIN: AEE01362P238), the largest integrated healthcare platform in the Middle East, today announced its financial results for the period ended March 31, 2024. In Q1 2024, PureHealth achieved robust revenue growth of 52%, reaching USD 1.7 billion. Particularly noteworthy is the 85% year-on-year increase in hospital revenue, totalling USD 1.3 billion. This growth was propelled by a 10% year-on-year surge in total patient volumes, reaching 1.5 million patients, as well as a 10% rise in bed occupancy rates to 71%. Furthermore, this upward trajectory was bolstered by the consolidation of recent 100% acquisitions of Sheikh Shakhbout Medical City ("SSMC") in Abu Dhabi and Circle Health Group in the United Kingdom. Commenting on the results the Group's Chairman, Hamad Al Hammadi, said: "PureHealth's performance is setting us on a path to joining the ranks of top-tier global healthcare ...